Celgene Europe has told the European Medicines Agency (EMEA) that its Pharmion subsidiary is withdrawing a marketing application for Orplatna because the EMEA’s Committee for Medicinal Products for Human Use does not think the cancer drug’s benefits outweigh its risks.
